Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tryptophan metabolism refers to a **complex network of biochemical pathways** responsible for the breakdown and utilization of tryptophan, an essential amino acid. It is not a single molecule or receptor but encompasses several distinct enzymatic routes: 1. **Kynurenine Pathway:** The primary route in mammals, catalyzed by tryptophan 2,3-dioxygenase (TDO) in the liver and indoleamine 2,3-dioxygenase (IDO) extrahepatically. This leads to production of neuroactive metabolites such as kynurenic acid and quinolinic acid. Dysregulation is implicated in cancer immune escape and neurodegeneration[1][4][5]. 2. **Serotonin Pathway:** In serotonergic neurons and some peripheral tissues, tryptophan is converted by tryptophan hydroxylase into serotonin—a key neurotransmitter—and further into melatonin via N-acetylserotonin[1][7]. 3. **Indole Pathways:** In gut microbiota, tryptophan can be metabolized into indoles that modulate host immunity through receptors like aryl hydrocarbon receptor; these microbial products influence mucosal homeostasis and inflammation[1][4]. Because "tryptophan metabolism" describes a set of interconnected pathways rather than a discrete molecular target such as an enzyme or receptor, it does *not* fit standard definitions used for therapeutic targets like "receptor," "enzyme," or "transporter." Instead, individual enzymes within these pathways—such as IDO1/IDO2/TDO—are considered drug targets due to their roles in disease processes including cancer immunosuppression and chronic inflammation[5]. Drugs have been developed against these specific enzymes rather than against “tryptophan metabolism” as a whole. Therefore: > The entry “Tryptophan metabolism” is not itself a canonical therapeutic target but rather describes multiple biological processes involving many potential druggable proteins. If you are seeking structured information on actionable targets within this system—for example “indoleamine 2,3-dioxygenase 1”—those should be specified individually. **Summary judgment:** “Tryptophan metabolism” is too broad/vague to serve directly as a canonical molecular target; it should be replaced with more precise entries corresponding to its constituent enzymes or receptors involved in disease-relevant biology.[1][4][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tryptophan metabolism.